Bristol-Myers Squibb Co. discovers, develops, licenses, manufactures and markets biopharmaceuticals worldwide. It offers products in hematology, oncology, cardiovascular and immunology therapeutic classes. It has agreements with Pfizer and Otsuka Pharmaceutical Co., Ltd.
Revenue TTM 44.3B
EBITDA TTM 18.8B
EBITDA margin TTM 42.4% P/S 2.94
P/S 2.94
Dividend yield 3.2%
Revenue TTM 44.3B
EBITDA TTM 18.8B
EBITDA margin TTM 42.4% P/S 2.94
P/S 2.94
Dividend yield 3.2%
Trade fermée: ordre d’arrêt atteint:
Nov 30